Early Post-operative Stimulated Serum Thyroglobulin: Role in Preventing Unnecessary Radioactive Iodine Treatment in Low to Intermediate Risk Papillary Thyroid Cancer.

AIM The aims of the study are to evaluate the predictive value of early post-operative stimulated thyroglobulin (sTg) analysis on the recurrence risk, and to define a cut-off value that is related to recurrence risk in low to intermediate risk papillary thyroid cancer (PTC). METHODS This retrospective cohort study included individuals who were diagnosed with PTC aged 18 years or older and had been operated by experienced surgeons of a tertiary university hospital between the years 2011 and 2021. The American Thyroid Association thyroid cancer guidelines version 2015 was used as the risk stratification system. Early sTg measurement obtained at 3-4 weeks after surgery when TSH >30 µIU/mL. Data was collected from the hospital database. A total of 328 patients who had post-operative early sTg values with negative anti-Tg antibodies were included. RESULTS The median age was 44 years. Of the 328 patients, 223 (68%) were women. The median tumor diameter was 11 mm. One hundred ninety-one patients (58.2%) had low risk and 137 (41.8%) had intermediate risk for recurrent disease. Of the 328 patients, 4.0% had recurrent disease. In multivariate Cox regression, post-operative early sTg value [OR: 1.070 (1.038-1.116), P = .000], and the pre-operative malign cytology [OR: 1.483 (1.080-2.245), P = .042] were independent risk factors for recurrence. On the ROC curve analysis, the cut-off value of early sTg was 4.1 ng/mL for those with recurrent disease. CONCLUSION This study demonstrated that early sTg could predict recurrent disease in patients with low to intermediate risk PTC. A cut-off of 4.1 ng/mL was identified with a high negative predictive value.

[1]  Hui Huang,et al.  Prevalence of Hashimoto Thyroiditis in Adults With Papillary Thyroid Cancer and Its Association With Cancer Recurrence and Outcomes , 2021, JAMA network open.

[2]  M. Magalhães,et al.  Does the Bethesda category predict aggressive features in differentiated thyroid cancer? , 2019, Archives of endocrinology and metabolism.

[3]  P. Rosário,et al.  Can the follow‐up of patients with papillary thyroid carcinoma of low and intermediate risk and excellent response to initial therapy be simplified using second‐generation thyroglobulin assays? , 2016, Clinical endocrinology.

[4]  P. Rosário,et al.  Low postoperative nonstimulated thyroglobulin as a criterion for the indication of low radioiodine activity in patients with papillary thyroid cancer of intermediate risk ‘with higher risk features’ , 2016, Clinical endocrinology.

[5]  S. Orlov,et al.  Serial post-surgical stimulated and unstimulated highly sensitive thyroglobulin measurements in low- and intermediate-risk papillary thyroid carcinoma patients not receiving radioactive iodine , 2016, Endocrine.

[6]  J. Youk,et al.  Prognostic role of the Bethesda System for conventional papillary thyroid carcinoma , 2016, Head & neck.

[7]  A. Gawande,et al.  Bethesda Categorization of Thyroid Nodule Cytology and Prediction of Thyroid Cancer Type and Prognosis. , 2016, Thyroid : official journal of the American Thyroid Association.

[8]  Jun Liang,et al.  Preablative Stimulated Thyroglobulin Correlates to New Therapy Response System in Differentiated Thyroid Cancer. , 2016, The Journal of clinical endocrinology and metabolism.

[9]  M. Plebani,et al.  Thyroglobulin measurement by highly sensitive assays: focus on laboratory challenges , 2015, Clinical chemistry and laboratory medicine.

[10]  I. Witterick,et al.  Post-operative stimulated thyroglobulin and neck ultrasound as personalized criteria for risk stratification and radioactive iodine selection in low- and intermediate-risk papillary thyroid cancer , 2015, Endocrine.

[11]  S. Park,et al.  Postoperative-stimulated serum thyroglobulin measured at the time of 131I ablation is useful for the prediction of disease status in patients with differentiated thyroid carcinoma. , 2013, Surgery.

[12]  Sebastiano Filetti,et al.  Papillary thyroid cancer: time course of recurrences during postsurgery surveillance. , 2013, The Journal of clinical endocrinology and metabolism.

[13]  P. Rosário,et al.  Postoperative stimulated thyroglobulin of less than 1 ng/ml as a criterion to spare low-risk patients with papillary thyroid cancer from radioactive iodine ablation. , 2012, Thyroid : official journal of the American Thyroid Association.

[14]  Stephanie L. Lee,et al.  Factors determining the persistence or recurrence of well-differentiated thyroid cancer treated by thyroidectomy and/or radioiodine in the Boston, Massachusetts area: A retrospective chart review , 2011, Thyroid research.

[15]  J. Shah,et al.  Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. , 2010, Thyroid : official journal of the American Thyroid Association.

[16]  Mark Dowar,et al.  Application of post‐surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low‐risk papillary thyroid carcinoma , 2010, Head & neck.

[17]  S. Mandel,et al.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[18]  L. Ceriani,et al.  Postsurgery serum thyroglobulin disappearance kinetic in patients with differentiated thyroid carcinoma , 2009, Head & neck.

[19]  S. Kruijff,et al.  Early postoperative stimulated serum thyroglobulin quantifies risk of recurrence in papillary thyroid cancer. , 2019, Surgery.